Compare Enveric Biosciences Inc (ENVB) vs Upstart Holdings Inc (UPST) Price & Performance

ENVB trades at $1.41, up 6.82% in the last session. The stock shows a bearish technical trend with moving averages signaling sell, but oscillators are neutral. Financially, the company reported a net loss of $8.77M for 2025, with negative ROE and ROA, though it consistently beat EPS expectations. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003.

Outlook is speculative with high risk due to negative profitability and cash burn, offset by strong analyst buy ratings (75%) and positive clinical updates. Key risks include funding needs and drug development hurdles, while catalysts hinge on regulatory milestones and partnership news.

Upstart Holdings (UPST) trades at $30.86, down 2.71% today, with a bearish technical signal from moving averages but oversold RSI conditions. The company reported a return to profitability in 2025 with $1.02B revenue and $53.60M net income, though recent Q1 2026 earnings missed expectations. Analyst sentiment is divided with a $42.00 consensus price target, while cash flow trends show improved but still negative operational cash generation.

UPST presents a high-risk, high-reward opportunity with strong AI lending growth potential but faces execution risks and margin pressure. The stock's current valuation at 77x P/E demands flawless execution of expansion into auto and home loans. Near-term performance hinges on Q2 2026 results due August 4, 2026, with investors watching for sustained profitability and funding stability.